SCHEMBL3014607

SCHEMBL3014607

Cc1ccc(C)c(Cc2csc(N3CCC(S(=O)(=O)c4c(F)c(Br)cc(F)c4Br)CC3)n2)c1

nearest known ligand 0.33

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DNM1L O00429 9/20 0.33
AR P10275 1/20 0.32
F2RL3 Q96RI0 1/20 0.31
SMN1; SMN2 Q16637 3/20 0.31
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
HTR6 P50406 1/20 0.30
ALDH1A1 P00352 1/20 0.30
CYP1A2 P05177 1/20 0.30
POLB P06746 1/20 0.30
MAPT P10636 1/20 0.30
CYP2C9 P11712 1/20 0.30
HPGD P15428 1/20 0.30
CYP2C19 P33261 1/20 0.30
HTT P42858 1/20 0.30
KMT2A Q03164 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2997493 0.91 NPC1 (0.34) DNM1LARF2RL3SMN1; SMN2NPC1
SCHEMBL3003296 0.89 DNM1L (0.34) DNM1LF2RL3SMN1; SMN2NPC1RAB9A
SCHEMBL3015404 0.88 AR (0.36) DNM1LARSMN1; SMN2NPC1RAB9A
SCHEMBL3014739 0.88 F2RL3 (0.32) DNM1LARF2RL3SMN1; SMN2NPC1
SCHEMBL3012892 0.88 DNM1L (0.32) DNM1LF2RL3SMN1; SMN2NPC1RAB9A
SCHEMBL3004564 0.87 DNM1L (0.34) DNM1LF2RL3KMT2A
SCHEMBL3014778 0.87 DNM1L (0.33) DNM1LARF2RL3SMN1; SMN2NPC1
SCHEMBL3012613 0.87 AR (0.33) DNM1LARF2RL3SMN1; SMN2NPC1
SCHEMBL3015605 0.87 SMN1; SMN2 (0.36) ARSMN1; SMN2RAB9AHTR6ALDH1A1
SCHEMBL3010354 0.86 DNM1L (0.34) DNM1LF2RL3HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA DNM1L 180/4885AR 3801/4885F2RL3 3732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.